share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  May 1 01:16
Summary by Futu AI
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ as BDRX, has announced that its licensor Emtora Biosciences will present the results of a Phase 2 clinical trial of eRapa for Familial Adenomatous Polyposis (FAP) at the Digestive Disease Week annual meeting in Washington DC, scheduled for May 18-21, 2024. The trial's six-month data will be presented by Principal Investigator Carol Burke, MD. Biodexa had previously announced on April 26, 2024, an exclusive worldwide licensing agreement with Emtora for the development and commercialization of eRapa. eRapa, a proprietary oral tablet formulation of rapamycin, is designed to improve bioavailability and reduce toxicity. It has been granted Orphan Designation in the US for FAP, a condition characterized by the proliferation of polyps in the colon and/or rectum that can lead to cancer if untreated. Biodexa's pipeline also includes tolimidone for type 1 diabetes and MTX110 for rare/orphan brain cancer indications. The company is headquartered in Cardiff, UK, and focuses on developing innovative products for diseases with unmet medical needs.
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ as BDRX, has announced that its licensor Emtora Biosciences will present the results of a Phase 2 clinical trial of eRapa for Familial Adenomatous Polyposis (FAP) at the Digestive Disease Week annual meeting in Washington DC, scheduled for May 18-21, 2024. The trial's six-month data will be presented by Principal Investigator Carol Burke, MD. Biodexa had previously announced on April 26, 2024, an exclusive worldwide licensing agreement with Emtora for the development and commercialization of eRapa. eRapa, a proprietary oral tablet formulation of rapamycin, is designed to improve bioavailability and reduce toxicity. It has been granted Orphan Designation in the US for FAP, a condition characterized by the proliferation of polyps in the colon and/or rectum that can lead to cancer if untreated. Biodexa's pipeline also includes tolimidone for type 1 diabetes and MTX110 for rare/orphan brain cancer indications. The company is headquartered in Cardiff, UK, and focuses on developing innovative products for diseases with unmet medical needs.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.